Stay up to date

News

see all news
University of Naples Federico II is implementing and evaluating Proclarix® to make it available in Italy

May 4, 2021

Zhengzhou University Henan Cancer Hospital (ZUHCH) and Proteomedix enter into a cooperation to clinically validate biomarker tests and bioinformatics for prostate cancer diagnostics

January 14, 2021

Publications

see all publications
Development and validation of a novel multivariate risk score to guide biopsy decision for the diagnosis of clinically significant prostate cancer.

Klocker H, Golding B, Weber S, Steiner E, Tennstedt P, Keller T, Schiess R, Gillessen S, Horninger W, Steuber T. BJUI Compass. 2020;1:15–20.

Neuer diagnostischer Prozess des Prostatakarzinoms

Engeler D, Korte W, Schiess R. Pipette - Swiss Laboratory Medicine 2020;3:24-26

Events

see all events
Postponed to Dec 13th-17th, 2020 - 2020 AACC Annual Scientific Meeting & Clinical Lab Expo

Chicago, US

Sep 23rd-26th, 2020 - Jahreskongress der Deutschen Gesellschaft für Urologie e.V.

Leipzig, DE

Resources

see all resources
Application note - Implementation of Proclarix in the workflow of a clinical laboratory
Analytical validation of the Proclarix Risk Score for the diagnosis of prostate cancer
Analytical performance of automated thrombospondin-1 and cathepsin D immunoassays for prostate cancer risk assessment